Affordable Access

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.

Authors
  • Pp, Ho
  • Pj, Ruiz
  • Emanual Maverakis
  • Db, Stevens
  • Cc, Bernard
  • R, Martin
  • Vk, Kuchroo
  • Jm, Van Noort
  • Cp, Genain
  • S, Amor
  • T, Olsson
  • Pj, Utz
  • H, Garren
  • L, Steinman
  • Wh, Robinson
  • P, Fontoura
  • Bj, Lee
  • He, De Vegvar
  • J, Tom
  • R, Pedotti
  • And 3 more
Type
Published Article
Journal
Nature Biotechnology
Publisher
Springer Nature
Volume
21
Issue
9
Pages
1033–1033
Source
maverakislab-ucdavis dermatology-ucdavis
License
Unknown

Abstract

The diversity of autoimmune responses poses a formidable challenge to the development of antigen-specific tolerizing therapy. We developed myelin proteome microarrays to profile the evolution of autoantibody responses in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). Increased diversity of autoantibody responses in acute EAE predicted a more severe clinical course. Chronic EAE was associated with previously undescribed extensive intra- and intermolecular epitope spreading of autoreactive B-cell responses. Array analysis of autoantigens targeted in acute EAE was used to guide the choice of autoantigen cDNAs to be incorporated into expression plasmids so as to generate tolerizing vaccines. Tolerizing DNA vaccines encoding a greater number of array-determined myelin targets proved superior in treating established EAE and reduced epitope spreading of autoreactive B-cell responses. Proteomic monitoring of autoantibody responses provides a useful approach to monitor autoimmune disease and to develop and tailor disease- and patient-specific tolerizing DNA vaccines.

Report this publication

Statistics

Seen <100 times